Patent · US Active

Oncolytic virotherapy for the therapy of ewing'S sarcoma

US9333225B2 · kind B2 · utility

2Cited by

0References

3Claims

0Family size

Assignee

Deutsches Krebsforschungszentrum · DE

Inventors

Zoltan Kis · Taleqan, IR
Jeaninne Lacroix · Heidelberg, DE
Barbara Leuchs · Heidelberg, DE
Monika Frank-Stohr · Neckargerach, DE
Jorg Schlehofer · Leimen, DE
Jean Rommelaere · Heidelberg, DE

Key dates

Filing date	Dec 13, 2013
Grant date	May 10, 2016
Priority date	—
Expiry date	Dec 13, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14332
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a parvovirus for the treatment of mesenchymal tumors, preferably malignant bone tumors such as localized and metastasized bone tumors, in particular osteosarcoma and Ewing's sarcoma. A preferred parvovirus includes a replication competent parvovirus H-1PV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.